Skip to main content

Advertisement

Table 1 Joint-preserving regenerative therapy-based core decompression

From: Joint-preserving regenerative therapy for patients with early-stage osteonecrosis of the femoral head

First author year/design Technique Number of hips (precollapse) Background factors for ONFH (%) Mean age (years) Mean follow-up (years) Hip survivorship (%)
Tsao [34] 2005/P CD 94 S 41, A 24, I 30, others 5 43 4.0 80.4
TR
Veillette [35] 2006/R CD 50 S 45, A 3, I 26, T 10, others 16 35 4.0 66.7
TR
Floerkemeier [36] 2011/P CD 23 NR 40 1.4 43.5
TR
Yu [37] 2015/P CD 6 S 5, A 68, I 21, T 5 48 1.4 50.0
CaSO4/CaPO4
Hernigou [16] 2009/P CD 534 S 19, SCD 31, I 28 39 13.0 82.4
BMMNC
Gangji [13] 2011/RCT CD 11 S 82, A 9, I 9 45.7 5.0 27.3
Gangji [13] 2011/RCT CD 13 S 85, A 8, I 8 42.2 5.0 76.9
BMMNC
Civinini [41] 2012/P CD, BMC, 30 S 49, A 35, I 16 43.9 1.7 83.3
CaSO4/CaPO4
Yamasaki [42] 2010/R CD 9 S 22, A 44, I 33 49 2.4 0
HA
Yamasaki [42] 2010/R CD, BMMNC, 27 S 73, A 20, I 7 41 2.4 56.7
HA
Lieberman [17] 2004/P CD, FBG 16 S 76, A 18, S&A 6 47 4.4 87.5
rhBMP 50 mg
Papanagiotou [43] 2014/P CD, FBG 5 S 40, A 20, I 40 32 4.0 80.0
rhBMP 3.5 g
Kuroda [23] 2015/P CD 10 S 80, A 20 39.8 1.0 90.0
rhFGF-2 800 μg
  1. P prospective study, R retrospective study, RCT randomized clinical trial, CD core decompression, TR tantalum rod, BMMNC bone marrow mononuclear cell, BMC bone marrow cell, HA hydroxyapatite, FBG fibular bone graft, rhBMP recombinant human bone morphogenetic protein, ONFH osteonecrosis of the femoral head, S steroid use, A alcohol intake, I idiopathic, T trauma, NR not reported, SCD sickle cell disease